Cargando…

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimberg, Lina Y, Dimberg, Anna, Ivarsson, Karolina, Fryknäs, Mårten, Rickardson, Linda, Tobin, Gerard, Ekman, Simon, Larsson, Rolf, Gullberg, Urban, Nilsson, Kenneth, Öberg, Fredrik, Wiklund, Helena Jernberg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488543/
https://www.ncbi.nlm.nih.gov/pubmed/22838736
http://dx.doi.org/10.1186/1471-2407-12-318
_version_ 1782248634471940096
author Dimberg, Lina Y
Dimberg, Anna
Ivarsson, Karolina
Fryknäs, Mårten
Rickardson, Linda
Tobin, Gerard
Ekman, Simon
Larsson, Rolf
Gullberg, Urban
Nilsson, Kenneth
Öberg, Fredrik
Wiklund, Helena Jernberg
author_facet Dimberg, Lina Y
Dimberg, Anna
Ivarsson, Karolina
Fryknäs, Mårten
Rickardson, Linda
Tobin, Gerard
Ekman, Simon
Larsson, Rolf
Gullberg, Urban
Nilsson, Kenneth
Öberg, Fredrik
Wiklund, Helena Jernberg
author_sort Dimberg, Lina Y
collection PubMed
description BACKGROUND: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM. METHODS: To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS). RESULTS: To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered. CONCLUSION: We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization.
format Online
Article
Text
id pubmed-3488543
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34885432012-11-05 Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma Dimberg, Lina Y Dimberg, Anna Ivarsson, Karolina Fryknäs, Mårten Rickardson, Linda Tobin, Gerard Ekman, Simon Larsson, Rolf Gullberg, Urban Nilsson, Kenneth Öberg, Fredrik Wiklund, Helena Jernberg BMC Cancer Research Article BACKGROUND: Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM. METHODS: To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS). RESULTS: To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered. CONCLUSION: We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization. BioMed Central 2012-07-28 /pmc/articles/PMC3488543/ /pubmed/22838736 http://dx.doi.org/10.1186/1471-2407-12-318 Text en Copyright ©2012 Dimberg et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dimberg, Lina Y
Dimberg, Anna
Ivarsson, Karolina
Fryknäs, Mårten
Rickardson, Linda
Tobin, Gerard
Ekman, Simon
Larsson, Rolf
Gullberg, Urban
Nilsson, Kenneth
Öberg, Fredrik
Wiklund, Helena Jernberg
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title_full Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title_fullStr Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title_full_unstemmed Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title_short Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
title_sort stat1 activation attenuates il-6 induced stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488543/
https://www.ncbi.nlm.nih.gov/pubmed/22838736
http://dx.doi.org/10.1186/1471-2407-12-318
work_keys_str_mv AT dimberglinay stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT dimberganna stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT ivarssonkarolina stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT fryknasmarten stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT rickardsonlinda stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT tobingerard stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT ekmansimon stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT larssonrolf stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT gullbergurban stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT nilssonkenneth stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT obergfredrik stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma
AT wiklundhelenajernberg stat1activationattenuatesil6inducedstat3activitybutdoesnotalterapoptosissensitivityinmultiplemyeloma